Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Cochrane Database of Systematic Reviews · 17.04.2023 · 2023 (4)
DOI: 10.1002/14651858.cd015849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, online erschienen am 17.04.2023. Verfasst von Patrizia Natale und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: This review aims to assess the benefits and harms of GLP‐1 receptor agonists to treat diabetes in people with CKD.
Zitieren
APA
Natale, P., Palmer, S. C., Tunnicliffe, D. J., Toyama, T., & Strippoli, G. F. (2023). Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database of Systematic Reviews, 2023(4). https://doi.org/10.1002/14651858.cd015849
Vancouver
Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database of Systematic Reviews. 2023;2023(4). doi:10.1002/14651858.cd015849
BibTeX
@article{Natale2023,
author = {Natale, Patrizia and Palmer, Suetonia C and Tunnicliffe, David J and Toyama, Tadashi and Strippoli, Giovanni FM},
title = {Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes},
journal = {Cochrane Database of Systematic Reviews},
year = {2023},
volume = {2023},
number = {4},
doi = {10.1002/14651858.cd015849}
}
EUVIMED